Susquehanna International Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-28,710
| Closed | -$271K | – | 12764 |
|
|
2025
Q1 | $271K | Sell |
28,710
-15,970
| -36% | -$186K | ﹤0.01% | 10281 |
|
|
2024
Q4 | $550K | Buy |
44,680
+33,659
| +305% | +$475K | ﹤0.01% | 8435 |
|
|
2024
Q3 | $165K | Sell |
11,021
-9,535
| -46% | -$140K | ﹤0.01% | 10654 |
|
|
2024
Q2 | $278K | Buy |
+20,556
| New | +$304K | ﹤0.01% | 9629 |
|
|
2024
Q1 | – | Sell |
-40,027
| Closed | -$539K | – | 12299 |
|
|
2023
Q4 | $539K | Buy |
40,027
+3,597
| +10% | +$39.3K | ﹤0.01% | 8477 |
|
|
2023
Q3 | $399K | Sell |
36,430
-2,929
| -7% | -$35.7K | ﹤0.01% | 8753 |
|
|
2023
Q2 | $509K | Buy |
39,359
+24,688
| +168% | +$323K | ﹤0.01% | 8269 |
|
|
2023
Q1 | $176K | Sell |
14,671
-22,490
| -61% | -$307K | ﹤0.01% | 10751 |
|
|
2022
Q4 | $510K | Sell |
37,161
-7,315
| -16% | -$107K | ﹤0.01% | 7813 |
|
|
2022
Q3 | $652K | Buy |
44,476
+31,374
| +239% | +$506K | ﹤0.01% | 7747 |
|
|
2022
Q2 | $199K | Buy |
13,102
+2,858
| +28% | +$43.8K | ﹤0.01% | 10639 |
|
|
2022
Q1 | $184K | Sell |
10,244
-10,335
| -50% | -$196K | ﹤0.01% | 11335 |
|
|
2021
Q4 | $490K | Buy |
20,579
+10,712
| +109% | +$298K | ﹤0.01% | 9269 |
|
|
2021
Q3 | $299K | Sell |
9,867
-15,788
| -62% | -$477K | ﹤0.01% | 10605 |
|
|
2021
Q2 | $817K | Buy |
25,655
+14,940
| +139% | +$451K | ﹤0.01% | 8309 |
|
|
2021
Q1 | $319K | Buy |
+10,715
| New | +$349K | ﹤0.01% | 10478 |
|
|
2020
Q4 | – | Sell |
-32,552
| Closed | -$892K | – | 11064 |
|
|
2020
Q3 | $892K | Buy |
32,552
+24,408
| +300% | +$653K | ﹤0.01% | 6387 |
|
|
2020
Q2 | $222K | Sell |
8,144
-32,906
| -80% | -$808K | ﹤0.01% | 8855 |
|
|
2020
Q1 | $814K | Sell |
41,050
-1,836
| -4% | -$39.6K | ﹤0.01% | 5851 |
|
|
2019
Q4 | $1M | Buy |
42,886
+13,276
| +45% | +$281K | ﹤0.01% | 5511 |
|
|
2019
Q3 | $550K | Buy |
+29,610
| New | +$601K | ﹤0.01% | 7083 |
|
|
2019
Q2 | – | Sell |
-17,956
| Closed | -$377K | – | 10270 |
|
|
2019
Q1 | $377K | Sell |
17,956
-43,876
| -71% | -$921K | ﹤0.01% | 6809 |
|
|
2018
Q4 | $1.17M | Buy |
61,832
+20,050
| +48% | +$418K | ﹤0.01% | 4395 |
|
|
2018
Q3 | $1.04M | Buy |
41,782
+9,974
| +31% | +$245K | ﹤0.01% | 5145 |
|
|
2018
Q2 | $768K | Buy |
+31,808
| New | +$857K | ﹤0.01% | 5930 |
|
|
2017
Q4 | – | Sell |
-8,821
| Closed | -$239K | – | 9296 |
|
|
2017
Q3 | $239K | Buy |
+8,821
| New | +$215K | ﹤0.01% | 7750 |
|
|
2016
Q4 | – | Sell |
-48,628
| Closed | -$1.25M | – | 9609 |
|
|
2016
Q3 | $1.25M | Buy |
48,628
+15,674
| +48% | +$386K | ﹤0.01% | 4376 |
|
|
2016
Q2 | $745K | Buy |
+32,954
| New | +$753K | ﹤0.01% | 5418 |
|
|
2016
Q1 | – | Sell |
-24,256
| Closed | -$693K | – | 9053 |
|
|
2015
Q4 | $693K | Buy |
+24,256
| New | +$698K | ﹤0.01% | 6164 |
|
Other funds holding CNCR
Susquehanna International Group's CNCR Position: Q2 2025 in Review
Susquehanna International Group sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 28,710 shares — an estimated $271K sold.
Susquehanna International Group first reported a position in CNCR in Q4 2015 and held it in 29 quarters. The position peaked at $1.25M in Q3 2016. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.
- Susquehanna International Group reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
- Susquehanna International Group sold 28,710 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $271K.
- Susquehanna International Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and held it in 29 quarters.
- Susquehanna International Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1.25M in Q3 2016.
- 1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.